Cargando…

Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat

BACKGROUND: Apart from simple steatosis, the non-alcoholic steatohepatitis (NASH) can progress into liver fibrosis and cirrhosis. To date, however, no widely accepted therapeutic modalities have been established against NASH in the clinical practice. To find out promising new therapeutic agents, it...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoshiji, Hitoshi, Noguchi, Ryuichi, Ikenaka, Yasuhide, Namisaki, Tadashi, Kitade, Mitsuteru, Kaji, Kosuke, Shirai, Yusaku, Yoshii, Junichi, Yanase, Koji, Yamazaki, Masaharu, Tsujimoto, Tatsuhiro, Kawaratani, Hideto, Akahane, Takemi, Aihara, Yosuke, Fukui, Hiroshi
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686718/ https://www.ncbi.nlm.nih.gov/pubmed/19416517 http://dx.doi.org/10.1186/1756-0500-2-70

Ejemplares similares

The vascular endothelial growth factor (VEGF) receptor-2 is a major regulator of VEGF-mediated salvage effect in murine acute hepatic failure
por: Namisaki, Tadashi, et al.
Publicado: (2010)

Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic Steatohepatitis
por: Tsuji, Yuki, et al.
Publicado: (2020)

The Angiotensin II Receptor Blocker Losartan Sensitizes Human Liver Cancer Cells to Lenvatinib-Mediated Cytostatic and Angiostatic Effects
por: Takagi, Hirotetsu, et al.
Publicado: (2021)

Acylcarnitine: Useful biomarker for early diagnosis of hepatocellular carcinoma in non-steatohepatitis patients
por: Takaya, Hiroaki, et al.
Publicado: (2019)

Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model
por: DOUHARA, AKITOSHI, et al.
Publicado: (2015)

ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma
por: Takaya, Hiroaki, et al.
Publicado: (2019)

Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity
por: Kaji, Kosuke, et al.
Publicado: (2017)

Development of hepatocellular carcinoma in a patient 13 years after sustained virological response to interferon against chronic hepatitis C: a case report
por: Mashitani, Tsuyoshi, et al.
Publicado: (2009)

Exogenous Administration of Low-Dose Lipopolysaccharide Potentiates Liver Fibrosis in a Choline-Deficient l-Amino-Acid-Defined Diet-Induced Murine Steatohepatitis Model
por: Nakanishi, Keisuke, et al.
Publicado: (2019)

Oral administration of fructose exacerbates liver fibrosis and hepatocarcinogenesis via increased intestinal permeability in a rat steatohepatitis model
por: Seki, Kenichiro, et al.
Publicado: (2018)

Large cell neuroendocrine carcinoma presenting with neck swelling in the submandibular gland: a case report
por: Kawaratani, Hideto, et al.
Publicado: (2013)

Acyclic retinoid and angiotensin-II receptor blocker exert a combined protective effect against diethylnitrosamine-induced hepatocarcinogenesis in diabetic OLETF rats
por: Nishimura, Norihisa, et al.
Publicado: (2018)

Association between Equol Production Status and Nonalcoholic Steatohepatitis
por: Akahane, Takemi, et al.
Publicado: (2021)

Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis
por: Fujinaga, Yukihisa, et al.
Publicado: (2020)

Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis
por: Ozutsumi, Takahiro, et al.
Publicado: (2020)

Serum angiotensin-converting enzyme level for evaluating significant fibrosis in chronic hepatitis B
por: Noguchi, Ryuichi, et al.
Publicado: (2017)

DNA methylation of angiotensin II receptor gene in nonalcoholic steatohepatitis-related liver fibrosis
por: Asada, Kiyoshi, et al.
Publicado: (2016)

Hydralazine Sensitizes to the Antifibrotic Effect of 5-Aza-2′-deoxycytidine in Hepatic Stellate Cells
por: Asada, Kiyoshi, et al.
Publicado: (2020)

Novel oral plasminogen activator inhibitor-1 inhibitor TM5275 attenuates hepatic fibrosis under metabolic syndrome via suppression of activated hepatic stellate cells in rats
por: Noguchi, Ryuichi, et al.
Publicado: (2020)

VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma
por: Takaya, Hiroaki, et al.
Publicado: (2019)

Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection
por: Sato, Shinya, et al.
Publicado: (2019)

Periostin cross-reacts with the renin-angiotensin system during liver fibrosis development
por: Takeda, Kosuke, et al.
Publicado: (2017)

Lenvatinib prevents liver fibrosis by inhibiting hepatic stellate cell activation and sinusoidal capillarization in experimental liver fibrosis
por: Ogawa, Hiroyuki, et al.
Publicado: (2021)

The Effect of Inflammatory Cytokines in Alcoholic Liver Disease
por: Kawaratani, Hideto, et al.
Publicado: (2013)

A Case of Lobulated and Pedunculated Duodenal Hyperplastic Polyp Treated with Snare Polypectomy
por: Kawaratani, Hideto, et al.
Publicado: (2011)

Treatment of long-segment Barrett’s adenocarcinoma by complete circular endoscopic submucosal dissection: a case report
por: Kaneko, Miki, et al.
Publicado: (2018)

Dual therapy with zinc acetate and rifaximin prevents from ethanol-induced liver fibrosis by maintaining intestinal barrier integrity
por: Fujimoto, Yuki, et al.
Publicado: (2021)

Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis
por: Namisaki, Tadashi, et al.
Publicado: (2017)

Intestinal Permeability Is a Mechanical Rheostat in the Pathogenesis of Liver Cirrhosis
por: Nishimura, Norihisa, et al.
Publicado: (2021)

TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats
por: Kaya, Daisuke, et al.
Publicado: (2019)

Identification of the Response-Related Biomarker of Bimonthly Hepatic Arterial Infusion Chemotherapy
por: Moriya, Kei, et al.
Publicado: (2021)

Rifaximin enhances the L-carnitine-mediated preventive effects on skeletal muscle atrophy in cirrhotic rats by modulating the gut-liver-muscle axis
por: Murata, Koji, et al.
Publicado: (2022)

The Ratio of von Willebrand Factor Antigen to ADAMTS13 Activity: Usefulness as a Prognostic Biomarker in Acute-on-Chronic Liver Failure
por: Takaya, Hiroaki, et al.
Publicado: (2023)

Liver Abscesses after Peritoneal Venous Shunt
por: Kawaratani, Hideto, et al.
Publicado: (2013)

Glycogenic Hepatopathy in Type 1 Diabetes Mellitus
por: Asada, Shohei, et al.
Publicado: (2017)

A Patient with Hepatocellular Carcinoma with Isolated Right Atrial Metastases
por: Takaya, Hiroaki, et al.
Publicado: (2017)

Increased Endotoxin Activity Is Associated with the Risk of Developing Acute-on-Chronic Liver Failure
por: Takaya, Hiroaki, et al.
Publicado: (2020)

Spontaneously ruptured hepatocellular carcinoma in Fontan-associated liver disease: A case report
por: Kubo, Takahiro, et al.
Publicado: (2020)

Association between Non-Alcoholic Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study
por: Akahane, Takemi, et al.
Publicado: (2020)

Zinc Administration and Improved Serum Markers of Hepatic Fibrosis in Patients with Autoimmune Hepatitis
por: Moriya, Kei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jpucp322u27qvsh68ned1fd3s2